CDKN2AIPNLP1: A Potential Drug Target and Biomarker (G391169)

Target Name: CDKN2AIPNLP1

NCBI ID: G391169

CDKN2AIPNLP1

Other Name(s): CDKN2A interacting protein N-terminal like pseudogene 1

CDKN2AIPNLP1: A Potential Drug Target and Biomarker

Abstract:

CDKN2AIPNLP1 (CDKN2A interacting protein N-terminal like pseudogene 1) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its unique structure and function have drawn significant interest in the scientific community, and several studies have investigated its role in various biological processes. In this article, we will provide an overview of CDKN2AIPNLP1, including its structure, function, and potential as a drug target and biomarker.

Introduction:

CDKN2A is a key regulator of gene expression in the cell cycle, and its dysfunction has been implicated in numerous diseases, including cancer, neurodegenerative diseases, and developmental disorders. The IPNLP1 gene, located on the N-terminus of CDKN2A, has been identified as a potential drug target due to its unique structure and function.

Structure and Function:

CDKN2AIPNLP1 is a non-coding RNA molecule that has a length of 194 nucleotides and an open reading frame (ORF) of 19. The ORF starts at the N-terminus of CDKN2A and includes 11 exons. The CDKN2AIPNLP1 molecule has a unique feature, known as the \"N-terminal like pseudogene,\" which refers to the fact that the last exon of the CDKN2AIPNLP1 gene is similar to the last exon of the CDKN2A gene. This similarity has led to the assumption that CDKN2AIPNLP1 may be a functional pseudogene that is expressed in the cell cycle.

CDKN2AIPNLP1 functions as a negative regulator of CDKN2A by binding to its N-terminus and preventing its transcriptional activity. This interaction between CDKN2AIPNLP1 and CDKN2A has been confirmed by several in vitro and in vivo studies. These studies have shown that the binding of CDKN2AIPNLP1 to CDKN2A is stable and can be modulated by various factors, including growth conditions, doping, and RNA-binding protein (RBP) interactions.

CDKN2AIPNLP1 has also been shown to play a role in regulating the cell cycle and cell growth. In cell culture experiments, CDKN2AIPNLP1 has been shown to inhibit the G1 phase and promote the G2/M phase of the cell cycle, which may have implications for the development of cancer. Additionally, CDKN2AIPNLP1 has been shown to play a role in regulating cell survival and has been implicated in the development of neurodegenerative diseases.

Potential as a Drug Target:

The unique structure and function of CDKN2AIPNLP1 make it an attractive drug target. Several studies have investigated its potential as a drug target and have shown that it has the potential to intervene in various biological processes, including cancer, neurodegenerative diseases, and developmental disorders.

One of the potential advantages of CDKN2AIPNLP1 as a drug target is its promiscuity. Studies have shown that CDKN2AIPNLP1 can interact with a wide range of molecules, including proteins, RNA, and small molecules. This promiscuity makes it a potential target for a variety of drugs , which can be developed with minimal effort and high efficiency.

Another potential advantage of CDKN2AIPNLP1 as a drug target is its unique expression pattern. Studies have shown that CDKN2AIPNLP1 is expressed in most tissues and cells, but is generally more abundant in brain and spinal cord tissues. This unique expression pattern makes it a potential target for drugs that can cross the blood-brain barrier and target the brain.

In addition to its potential as a drug

Protein Name: CDKN2A Interacting Protein N-terminal Like Pseudogene 1

The "CDKN2AIPNLP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDKN2AIPNLP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets